Compounds for modulating cell proliferation

Details Compounds for modulating cell proliferation Compounds for modulating cell proliferation

2001-04-12

2004-10-05

Ramsuer, Robert W. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S390000, C558S392000, C558S402000, C558S403000, C558S445000, C568S442000, C514S523000, C514S528000, C514S701000, C514S238500, C514S424000, C514S521000, C556S405000, C544S157000, C544S158000, C544S159000, C548S579000

Reexamination Certificate

active

06800659

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to novel compounds which are useful for treating a variety of cell proliferative disorders such as cancer.
BACKGROUND OF THE INVENTION
A wide range of growth factors coordinate cell proliferation and differentiation. Malignant cells arise as a result of a stepwise progression of events that include the unregulated expression of growth factors or components of their signaling pathways. Tyrosine phosphorylation events initiated by receptor, cytoplasmic and nuclear kinases and regulated by phosphatases are central to these processes. Mutation, hyper-activation, translocation and overexpression of protein tyrosine kinases are all associated with tumorigenesis. In addition to increasing proliferative rates and immortalizing cells, overexpression of tyrosine kinases can lead to morphological transformation and cause anchorage independence, contributing to the promotion of migratory ability and possibly the induction of metastases.
Certain compounds with structures based upon mimicry of ATP or phosphotyrosine have been shown to be effective kinase inhibitors. Those based upon phosphotyrosine have been demonstrated to be the more specific tyrosine kinase inhibitors. Because of their ability to inhibit tyrosine phosphorylation, these compounds may alter cell responses to growth factors or other process driven by tyrosine kinase activity, including unregulated growth as the result of tyrosine kinase overexpression, mutation, or translocation. Inhibition of tyrosine kinases occupying a central role in proliferative signaling pathways, or in pathways regulating cell cytoskeletal structure, even temporary or incomplete inhibition, may be sufficient to switch a cancerous cell from a proliferative cycle into programmed cell death, or apoptosis. Death by apoptosis is most often observed upon effective treatment with tyrosine kinase inhibitors.
Selective inhibition of specific tyrosine kinases offers a method of targeting cancerous cell growth with a high degree of specificity and minimal toxicity to normally growing cells and tissues. Thus, specific inhibitors of tyrosine kinases have great potential as clinical anti-cancer treatments. A number of small molecules which act as tyrosine kinase inhibitors have been identified. For example, certain phenyl acrylonitrile compounds have been described as tyrosine kinase inhibitors, effective to inhibit cell proliferation (see for example, U.S. Pat. Nos. 5,891,917, 5,217,999, 5,773,476, 5,935,993, 5,656,655, 5,677,329 and 5,789,427).
Inhibition of tyrosine kinases offers one mechanism by which cell proliferation can be inhibited. One of skill in the art will appreciate that other mechanisms of inhibition may also be involved.
There is a need in the art to identify compounds that inhibit cell proliferation.
SUMMARY OF THE INVENTION
A number of novel compounds have now been identified that inhibit abnormal cell proliferation, for example cancer cell growth. The compounds do not inhibit the growth of normal cells.
Accordingly, the present invention includes compounds of Formula I and salts, solvates and hydrates thereof:
wherein
R
1
and R
2
are each independently selected from the group consisting of H, OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, O—Si(C
1-6
alkyl)(C
1-6
alkyl)(C
1-6
alkyl), NO
2
, CF
3
, OCF
3
and halo;
R
3
is selected from the group consisting of H, OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, O—Si(C
1-6
alkyl)(C
1-6
alkyl)(C
1-6
alkyl), NO
2
, halo and CH
2
—S—(CH
2
)
n
Ar;
R
4
is selected from the group consisting of C(X)R
5
, SO
3
Ar, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), P(O)(OH)
2
, P(O)(OC
1-6
alkyl)
2
, and C(NH
2
)═C(CN)
2
;
X is selected from O,S, NH and N—C
1-6
alkyl;
R
5
is selected from the group consisting of NH
2
, OH, NH(CH
2
)
p
Ar, NH(CH
2
)
p
OH, (CH
2
)
p
OC
1-6
alkyl, C
1-6
alkyl, C
1-6
alkoxy, NHNH
2
, NHC(O)NH
2
, NHC(O)C
1-6
alkoxy, N-morpholino and N-pyrrolidino;
Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from the group consisting of OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, NO
2
, CF
3
, OCF
3
and halo;
n is 0 to 4; and
p is 1-4.
The present invention further includes compounds of Formula II and salts, solvates and hydrates thereof:
wherein
R
1
and R
2
are each independently selected from the group consisting of H, OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, O—Si(C
1-6
alkyl)(C
1-6
alkyl)(C
1-6
alkyl), NO
2
, CF
3
, OCF
3
and halo;
R
3
is selected from the group consisting of H, OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, O—Si(C
1-6
alkyl)(C
1-6
alkyl)(C
1-6
alkyl), NO
2
, halo and CH
2
—S—(CH
2
)
n
Ar;
Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from the group consisting of OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, NO
2
, CF
3
, OCF
3
and halo;
R
6
is selected from the group consisting of Ar, OH and OC
1-6
alkyl;
X is selected from O and S;
n is 0-4; and
p is 1-4.
The present invention also provides compounds of Formula III and salts, solvates and hydrates thereof:
wherein
R
1
and R
2
are each independently selected from the group consisting of H, OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, O—Si(C
1-6
alkyl)(C
1-6
alkyl)(C
1-6
alkyl), NO
2
, CF
3
, OCF
3
and halo;
R
3
is selected from the group consisting of H, OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, O—Si(C
1-6
alkyl)(C
1-6
alkyl)(C
1-6
alkyl), NO
2
, halo and CH
2
—S—(CH
2
)
n
Ar;
Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from the group consisting of OH, C
1-6
alkyl, C
1-6
alkoxy, NH
2
, NH—C
1-6
alkyl, N(C
1-6
alkyl)(C
1-6
alkyl), SH, S—C
1-6
alkyl, NO
2
, CF
3
, OCF
3
and halo;
R
7
is selected from the group consisting of OH, NH
2
and OC
1-6
alkyl;
X is selected from O and S; and
n is 0-4.
According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent.
In accordance with a further aspect of the present invention, there is provided a method for modulating cell proliferation, preferably inhibiting cell proliferation comprising administering an effective amount of a compound of the invention to a cell or animal in need thereof. The invention also includes a use of a compound of the invention to modulate cell proliferation, preferably inhibit cell proliferation. The invention further includes a use of a compound of the invention to prepare a medicament to modulate cell proliferation, preferably inhibit cell proliferation.
In a preferred embodiment the present invention provides a method of inhibiting the proliferation of a cancer cell comprising administering an effective amount of a compound of the invention to a cell or animal in need thereof. The cancer cell treated may be any type of cancer including a leukemia, a lymphoma, myeloma, metastatic carcinoma, sarcoma or any other malignant transformation or any other malignancy. The invention also includes a use of a compound of the invention to modulate cancer cell proliferation, preferably inhibit cancer cell proliferation. The invention further includes a use of a compound of the invention to prepare a medicament to modulate cancer cell proliferation, preferably inhibit cancer cell proliferation.
In another aspect, the invention provides a method of modulating tyrosine kinase activity in a cell by administering an effective amount of a compound of the invention. In a further aspect, the invention provides a meth

Affiliated with

Also associated with

Rating

Compounds for modulating cell proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for modulating cell proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for modulating cell proliferation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3320734